Revolution Medicines, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RVMD | ERAS | RLAY | SNDX | GMAB | SMMT | |
|---|---|---|---|---|---|---|
| Market cap | 41.57B | 5.41B | 3.94B | 1.48B | 22.98B | 13.67B |
| P/E (TTM) | — | — | — | — | 29.7 | — |
| Forward P/E | -33.9 | -24.8 | -11.0 | -19.4 | 24.5 | -15.0 |
| Price/book | 15.9 | 13.4 | 4.4 | 97.9 | 3.7 | 21.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +308.32% | +541.49% | +198.18% | +8.10% | +14.11% | −21.24% |
| Today | +2.21% | −3.56% | +0.56% | −2.59% | +0.81% | −2.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RVMD news ›Luis Chia Appointed Senior Director of Global Commercial Development at Revolution Medicines
Luis Chia, Senior Director of Global Commercial Development, Early Pipeline and Exploratory Indications at Revolution Medicines, shared on LinkedIn: “I’m excited to share that I’ve joined Revolution Medicines as Senior Director, Global…
What Happens When Science Leads Us in an Unexpected Direction? – Revolution Medicines
“Our most defining moment wasn’t a breakthrough – it was a question. Early in Revolution Medicines’ journey, a promising research program didn’t deliver the results we hoped for. Rather than defend our hypothesis, we asked why and followed…
Revolution Medicines (RVMD) Stock Dips After FDA Review, But Analysts See Upside
Investors considering RVMD should weigh the potential clinical and commercial upside against the risks inherent in early-stage biotech development and valuation extremes. For ongoing updates and detailed financial data, explore the RVMD…
Revolution Medicines (RVMD) Shares Slide After FDA Review Highlights Daraxonrasib Efficacy Concerns
On October 08, 2026, shares of Revolution Medicines Inc (NASDAQ: RVMD) declined following an FDA review that cast uncertainty on the efficacy of its lead drug candidate daraxonrasib against KRAS mutations. The FDA documents emphasized that…
TD Cowen Maintains Buy on Revolution Medicines (RVMD) Despite Recent Stock Drop
The GF Score™ aggregates multiple financial and operational metrics to provide a snapshot of a company’s overall health and performance. Revolution Medicines’ GF Score™ of 27 out of 100 suggests weak overall fundamentals, primarily driven…
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
Propanc believes these mechanisms address residual drivers of resistance, dormancy, and metastasis that can persist after RAS pathway blockade – creating a scientific rationale for combination or sequential use with RAS inhibitors. A…
Revolution Medicines (NASDAQ:RVMD) Stock Falls 4.3% – Should You Sell?
Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report)’s stock price fell 4.3% during trading on Tuesday. The stock traded as low as $203.50 and last traded at $198.7030. 72,109 shares were traded during mid-day trading, a decline of…
24/7 Market News Highlights NeOnc, Revolution Medicines, Moderna, Merck, Johnson & Johnson and Genmab, AbbVie in 2026 Cancer Treatment Advances
2026 saw progress in treatments for pancreatic cancer, brain cancer, melanoma, multiple myeloma, and aggressive lymphoma, providing new hope for patients. NEO100 is an intranasal treatment showing promising survival rates for recurrent…
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Propanc plans to move PRP into a first-in-human study expected to enroll up to 50 patients with advanced solid tumors. Propanc Biopharma (PPCB) reported preclinical pancreatic cancer results for PRP, including more than 90% mean tumor…
How Revolution Medicines Inc - Ordinary Shares (RVMD) Affects Rotational Strategy Timing
Stock Traders Daily Key findings for Revolution Medicines Inc - Ordinary Shares (NASDAQ: RVMD) - Near-Term Strong Sentiment Could Influence Mid-Term Neutrality Toward Long-Term Positive Bias - Exceptional 33.5:1 risk-reward short setup…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
gurufocus.com3
-
markets.businessinsider.com2
-
defenseworld.net1
-
fool.com1
-
investegate.co.uk1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.